Latest Carcinoid Stories

The Philly NETs (neuroendocrine tumor cancers) and its patient community will celebrate the 3rd annual worldwide NET Cancer Awareness Day on November 10th at the Philadelphia Zoo with its inaugural 5K “Deb’s Run for The Stripes”. PhillyNETs is the sponsoring group in partnership with the Patients’ Project, a local nonprofit addressing the issue of health literacy. The Run will benefit University of Pennsylvania’s Abramson Cancer Center’s Neuroendocrine Tumor Program whose...

THE WOODLANDS, Texas, Oct. 12, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a registrational, Phase 3 clinical trial of telotristat etiprate, an investigational new drug candidate for the treatment of carcinoid syndrome. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate...

THE WOODLANDS, Texas, Oct. 12, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate. Results from the trial will be presented at the North American Neuroendocrine Tumor Society on Saturday, October 13, 2012 in San Diego, California. Carcinoid syndrome is a...

SAINT GENIS POUILLY, France, September 19, 2012 /PRNewswire/ -- Highlights - Lutathera(R) is the first theragnostic drug in Molecular Nuclear Medicine (MNM) to enter phase III clinical development - First European patient enrolled on July 20,2012; first US patient expected to be enrolled in Q4 2012 - Phase II results in progressive midgut carcinoid showed Progression-Free Survival of more than 44 months...

THE WOODLANDS, Texas, March 20, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the U.S. Food and Drug Administration (FDA) has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract and is characterized by severe diarrhea and flushing episodes with...

Combination treatment with octreotide shows improved results in tumors associated with carcinoid syndrome Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center. Results of the international, randomized, placebo-controlled...

THE WOODLANDS, Texas, Oct. 21, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that data from its Phase 2 clinical studies of telotristat etiprate (LX1032) will be presented this weekend at the annual meeting of the North American Neuroendocrine Tumor Society (NANETS) in Minneapolis, Minnesota. Data from a recently-completed placebo-controlled Phase 2 study in the...

CCAN sees an urgent need to generate publicity and financial support used in the fight to cure neuroendocrine cancers, such as the Neuroendocrine Islet Cell Cancer of the pancreas that claimed the life of Apple founder Steve Jobs. North Bellmore, New York (PRWEB) October 14, 2011 The Carcinoid Cancer Awareness Network, a non-profit patient advocacy group that provides support for cancer patients, has announced their 3rd Annual Zebra Walk and 8th Annual Gala. These are key events for...

THE WOODLANDS, Texas, Aug. 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract. It is characterized by...

EAST HANOVER, N.J., Feb. 9, 2011 /PRNewswire/ -- The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)(1). Data from the study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), were first presented last year at the 12th World...